Canopy Growth completed the acquistion of Canppy Health Innovations
CANOPY GROWTH STRENGTHENS COMMITMENT TO CANNABIS-BASED MEDICINES THROUGH COMPLETION OF CANOPY HEALTH INNOVATIONS ACQUISITION
Healthcare & Life Sciences
Akumi to acquire US $27.5M revenue business in florida
Akumin Inc. (TSX: AKU.U) t to acquire a freestanding, fixed-site outpatient diagnostic imaging business located in Florida for US $27.5 million.
Akumin completes US $35M bought deal financing
Akumin Inc. (TSX: AKU.U) completed bought deal offering of 8,750,000 common shares at US $4.00 for gross proceeds of US $35,000,000. Clarus Securities Inc. led the offering.
Akumin announces US $35M bought deal
Akumin (TSX: AKU.U) engaged Clarus Securities Inc. for a bought deal of 8,750,000 Common Shares at US $4.00 for gross proceeds of US $35,000,000
DiaMedica Therapeutics closes US $2.5M final tranche of private placemet
DiaMedica Therapeutics (TSX-V: DMA; OTCQB: DMCAF) closed second and final tranche of offering for gross proceeds of approximately US$2.5M. The company raised US $6.3M in two tranches.
Xenon Pharmaceuticals closes Teva and BVF transactions
Xenon Pharmaceuticals (NASDAQ: XENE) terminated collaborative development and license agreement with Teva Pharmaceuticals and closed share exchange transaction with Biotechnology Value Fund (BVF)
Profound Medical completes $34.5M bought deal
Profound Medical Corp. (TSX-V: PRN; OTCQX: PRFMF) closed previously announced bought for gross proceeds of $34.5M. Canaccord Genuity Corp. led the offering
Cognetivity Neurosciences trades on CSE
Cognetivity Neurosciences Ltd. (CSE: CGN) commenced trading on the Canadian Securities Exchange (CSE) under the ticker symbol “CGN”.
HLS Therapeutics and Automodular closes RTO merger
HLS Therapeutics Inc. and Automodular Corporation completed RTO transaction
Immunovaccine announces $12.M bought deal led byEchelon Wealth Partners
Immunovaccine Inc. (TSX: IMV; OTCQX: IMMVF) engaged Echelon Wealth Partners Inc. for a bought deal financing of 6,250,000 common shares at $2.00 per share for gross proceeds of $12.5 million
